Pacific Biosciences of California, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Mark David van Oene
- Full Time Employees
- 485
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 1305 O’Brien Drive Menlo Park CA United States 94025
- IPO Date
- Oct 26, 2010
- CIK
- 0001299130
- Website
- pacb.com
- Similar Companies
- Business
- Pacific Biosciences of California, Inc. (PacBio) designs, develops, and manufactures advanced sequencing solutions to resolve genetically complex problems in life sciences research and clinical applications; its core offerings include long-read HiFi sequencing systems such as the Revio production-scale platform delivering up to 120 Gb per SMRT Cell with SPRQ-Nx chemistry, the Vega benchtop system providing 60 Gb per SMRT Cell, and legacy Sequel II and Sequel IIe instruments; short-read sequencing via the Onso system powered by sequencing by binding (SBB) chemistry achieving 90% Q40 accuracy; consumables encompassing SMRTbell library preparation kits, reagent kits including ligase, buffers, exonucleases, flow cells, clustering, and sequencing reagents; and software solutions like SMRT Link for analysis, Paraphase variant caller, and applications for whole genome sequencing, targeted sequencing, epigenetics, RNA isoform sequencing, and PureTarget assays for repeat expansions and carrier screening. The company serves academic and governmental research institutions, genome centers, public health labs, hospitals, clinical research institutes, contract research organizations, pharmaceutical firms, and agricultural companies across the Americas, Europe, Middle East, Africa, Asia Pacific including China and Japan, and other regions through direct sales and distribution partners. Incorporated in 2000 and headquartered at 1305 O'Brien Drive in Menlo Park, California, PacBio operates in the biotechnology sector focusing on human genetics, plant and animal sciences, infectious disease, oncology, and emerging multiomic applications. Recent developments include the launch of SPRQ-Nx chemistry in 2025 targeting up to 40% reduction in HiFi genome sequencing costs to under $300 per genome at scale with beta testing on Revio starting November 2025 and commercial availability in 2026; expanded PureTarget portfolio with updated repeat expansion and new carrier screening panels plus 96-plex automation kits; distribution agreement with Haorui Gene in 2025 to promote platforms including Vega in China's clinical labs for blood typing genomics and precision medicine; Class III medical device approval in China for Sequel II CNDx system via partner Berry Genomics in November 2025; partnership with Epicycle for FiberSeq chromatin analysis integration; selection of Revio for the U.S. National Institute on Aging's Long Life Family Study sequencing up to 7,800 genomes and epigenomes, and the Korean Pangenome Reference Project for over 1,000 genomes; and publication of HiFi Solves EMEA Consortium preprint demonstrating 100% detection of pathogenic variants in complex regions.
Company News
Pacific Biosciences Q3: Another Revenue Guidance Cut
Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
PacBio Announces Third Quarter 2026 Financial Results
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
PacBio to Participate in Upcoming Investor Conferences
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
PacBio and Verily Health Announce Multi-Year Strategic Collaboration to Scale Long-Read Genomics for Biomedical AI
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
PacBio to Report Third Quarter 2026 Financial Results on November 4, 2026
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Why
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $2,058,244.65 in Stock
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
3 Biotech Stocks Put Traders Are Targeting Today
Pacific Biosciences of California (NASDAQ:PACB) Stock Sees Heavy Call Option Buying